Researching hypothetical scenario if Hanta26 spreads as fast as COVID did.
​
Assumptions for this scenario:
- Andes virus mutates or is confirmed to spread via casual airborne contact (COVID-level R0 of ~2.5-3+)
- CFR remains in the 30-40% range without ECMO; ~15-20% with it
- No existing vaccine, no specific antiviral treatment
---
## Week 1-3: Detection Lag & Denial Window
This is the most dangerous phase. Because Andes hantavirus symptoms (fever, muscle aches, fatigue) are indistinguishable from flu for the first 4-7 days, and because the current framing is "contained cruise ship outbreak," widespread community transmission would likely go undetected for **2-3 weeks minimum**.
The US specifically has a problem here: the CDC has undergone significant budget cuts and restructuring under the current administration. The pandemic early warning infrastructure — particularly PREDICT and related programs — were already gutted after COVID. Surveillance capacity is genuinely degraded compared to 2020.
Internationally, WHO's capacity is also hampered. The US formally re-withdrew from WHO under Trump's second term, which fractures the coordination layer that actually matters in the first 30 days.
**Realistic outcome:** Silent spread in South America (Argentina, Chile especially, since that's the endemic rodent zone), Europe from the Hondius passengers, and potentially early US seeding through travel — all before any coordinated alarm is raised.
---
## Week 3-6: Alarm Without Coordination
Hospitals in multiple countries start seeing unexplained severe pneumonia clusters. The pattern gets recognized. This is where it diverges hard from COVID based on the current political environment.
**US-specific:**
- RFK Jr. is HHS Secretary. His instinct on novel pathogen response is deeply skeptical of institutional public health framing. Expect significant internal friction before any federal mobilization.
- The current administration's ideological posture is strongly against mask mandates, lockdowns, or anything that reads as "COVID 2.0" — politically toxic. That messaging will delay federal action by **weeks**, not days.
- ECMO capacity in the US is approximately 200-300 centers with maybe 2,000-3,000 machines nationwide. At a 30-40% CFR with COVID-level spread, those fill within **days** of a true surge. ECMO is not scalable like ventilators.
- No federal stockpile protocol exists for hantavirus PPE escalation.
**Europe:**
Faster and more coordinated response than the US, but post-COVID political fatigue is real. Germany, France, Netherlands have functional public health infrastructure. Expect European nations to move toward containment measures 2-3 weeks ahead of the US.
**Global South:**
Argentina and Chile are ground zero if this is circulating in rodent populations across the continent. Their healthcare systems — particularly ECMO capacity — are extremely limited. Sub-Saharan Africa, South Asia: essentially no ECMO infrastructure. This becomes a mass casualty event in those regions almost immediately upon spread.
---
## Month 2-3: The Pivotal Window
This is where the 30-40% CFR changes everything compared to COVID. COVID's ~1% IFR allowed governments to delay, hedge, and half-measure their way through. **A 30% CFR cannot be politically managed the same way.** Bodies are visible fast.
At COVID-level spread with this CFR, projecting even conservatively:
- US with COVID's first wave pace (~30M infected in 6 months): **9-12 million deaths** in that window without effective intervention. That's not a scenario any administration can spin.
This is where the Trump administration dynamic gets complicated and somewhat unpredictable:
- The initial instinct will be to downplay (economic, political reasons)
- But the death toll visibility at 30% CFR makes denial untenable faster than COVID — probably by **week 6-8** of recognized community spread
- Expect an abrupt pivot to aggressive nationalism: border closures, domestic production orders (DPA invoked), and a blame-China or blame-WHO framing regardless of the actual origin
**What won't happen quickly:**
- Coordinated international response (US-WHO estrangement is real)
- A national mask mandate (politically impossible in this administration)
- School/business closures at federal level — this will be pushed entirely to states, creating a red/blue divergence in outcomes that is statistically measurable and brutal
---
## Month 3-6: Vaccine Race Under Different Constraints
Here's a key difference from COVID: **mRNA platform exists and proved itself**. Moderna and BioNTech could theoretically develop an Andes virus mRNA vaccine candidate in 60-90 days of intensive work. The platform is there.
But:
- RFK Jr.'s FDA is more skeptical of accelerated approval pathways
- The EUA framework that allowed COVID vaccine emergency authorization could face internal political resistance
- Anti-vax sentiment in the US is now significantly higher than 2020 — even if a vaccine arrives fast, uptake would be materially lower
Realistically, a functional vaccine at scale is **12-18 months out** — similar to COVID — but with worse uptake and more political friction around mandates.
**Globally:** COVAX and similar equity mechanisms are weaker now. Expect a repeat of the vaccine nationalism from 2020-2021, likely worse because the US is less engaged with multilateral frameworks.
---
## The Honest Macro Picture
If this goes COVID-level transmissible, the honest answer is: **this would be the worst infectious disease event in recorded human history**, likely surpassing the 1918 flu in absolute death toll given global population size. The 1918 flu had roughly a 2-3% CFR and killed 50-100 million. A 30% CFR pathogen at COVID spread is a civilization-level event.
The saving grace — and it's the reason this scenario probably doesn't materialize — is that viruses with very high CFR tend to burn through their hosts too fast and face strong evolutionary pressure to attenuate. Andes becoming both highly transmissible AND maintaining 30-40% lethality would be somewhat unusual virology. High CFR and high transmissibility are generally in tension.